

December 7, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub: Disclosure of Related Party Transactions for the half year ended 30th September 2020.
Ref: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 30th September 2020.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B Adi Reddy
Company Secretary

Encl: as above.



Aurobindo Pharma Limited

Disclosure of related party transactions on a consolidated basis for the half year ended 30 September 2020

(All amounts are in Indian Rupees in millions)

i) Names of related parties and description of relationship**a) Section 8 Wholly owned subsidiaries (Not Consolidated)**

Aurobindo Pharma Foundation (w.e.f. 20th July, 2020)

b) Joint ventures

Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)

Eugia Pharma Specialities Limited, India (Joint Venture of a step-down subsidiary, Curepro parenterals Ltd)

Tergene Biotech Private Limited, India

Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)

Purple Bellflower (Pty)Ltd, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)

Luoxin Aurovitas Pharn (Chengdu) Co. Ltd. (Joint Venture of a step-down subsidiary, Helix Healthcare B.V.)

Longxiang Pharma Taizhou Co. Ltd (Joint Venture of a step-down subsidiary, Helix Healthcare B.V.)

Novagen BBBEE Invest Co (Pty) Ltd (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)

c) Enterprises over which key management personnel or their relatives exercise significant influence

Pravesha Industries Private Limited, India

Sri Sai Packaging, India (Partnership firm)

Trident Chemphar Limited, India

Axis Clinicals Limited, India

Pranit Packaging Private Limited, India

SGD Pharma India Limited (formerly Cogent Glass Limited), India

Orem Access Bio Inc, India

Veritaz Healthcare Limited, India

Axis Clinicals LLC, USA

Crest Cellulose Private Limited, India

East Pharma Technologies, India (Partnership firm)

Axis Clinicals Latina SA DE CV, Mexico

Gelcaps Industries, India

Aurobindo Pharma Foundation, India (Trust)

Giyaaan Pharma Private Limited, India

Alcedo Pharmachem Private Limited, India

Ambipack Industries, India

d) Key managerial personnel

Mr. K. Nityananda Reddy, Whole-time Director

Dr. M. Sivakumaran, Whole-time Director

Mr. M. Madan Mohan Reddy, Whole-time Director

Mr. P. Sarath Chandra Reddy, Whole-time Director

Mr. N. Govindarajan, Managing Director

Mr. Santhanam Subramanian, Chief Financial Officer

Mr. B. Adi Reddy, Company Secretary

Mr. K. Ragunathan, Non-executive Chairman and Independent Director

Mr. M. Sitarama Murty, Independent Director

Dr. (Mrs.) Avnit Bimal Singh, Independent Director

Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director

Mrs.Savitha Mahajan, Independent Director

e) Relatives to key managerial personnel

Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumaran, Wholetime Director)

ii) Transactions with related parties**a. Transactions with Section 8 Wholly owned subsidiaries (Not Consolidated)**

	Half Year ended 30 September 2020
Aurobindo Pharma Foundation	
Contribution towards CSR activities	40.0

b. Transactions with joint ventures

	Half Year ended 30 September 2020
Raidurgam Developers Limited	
Investment in optionally convertible debentures	175.0
Interest accrued	22.8
Novagen Pharma (Pty) Limited, South Africa	
Sale of products	83.4
Sale of services	15.3
Dividend received	1.6
Eugia Pharma Specialities Ltd, India	
Sale of products	48.1
Purchases	195.7
Purchase of property, plant and equipment	3.1
Tergene Biotech Pvt. Ltd, India	
Investment in 10.5% Cumulative Redeemable Preference shares	21.5
Novagen BBBEE Invest Co (Pty) Ltd , South Africa	
Equity contribution	0.8



c. Transactions with enterprises over which key management personnel or their relatives exercise significant influence

Half Year ended
30 September 2020

Pravesha Industries Private Limited, India	
Sale of products	0.1
Sale of services	0.5
Purchases	1,809.8
Sri Sai Packaging, India	
Sale of products	0.2
Purchases	129.4
Axis Clinicals Limited, India	
Sale of products	0.2
Purchase of services	1,258.9
Axis Clinicals LLC, USA	
Purchase of services	497.6
Axis Clinicals Latina SA DE CV, Mexico	
Purchase of services	5.1
Trident Chemphar Limited, India	
Sale of products	0.2
Purchases	774.5
Purchase of services	67.7
Pranit Packaging Private Limited, India	
Purchases	134.1
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Purchases	581.0
Orem Access Bio Inc, India	
Sale of products	0.1
Purchases	235.5
Veritaz Healthcare Limited, India	
Sale of products	76.2
Rent received	0.2
Purchases	27.2
Crest Cellulose Private Limited, India	
Purchases	192.9
East Pharma Technologies, India	
Purchases	59.8
Sale of services	0.1
Gelcaps Industries, India	
Purchases	245.7
Aurobindo Pharma Foundation, India (Trust)	
Contribution towards CSR activities	110.0
Giyaan Pharma Private Limited, India	
Sale of products	28.9
Alcedo Pharmacepm Private Limited, India	
Purchases	141.6
Ambipack Industries, India	
Purchases	70.6

d. Transactions with key managerial personnel

Half Year ended
30 September 2020

Mr. K Nityananda Reddy	
Rent expense	1.4

e. Transactions with relatives of key managerial personnel

Half Year ended
30 September 2020

Salaries and other benefits*	3.3
------------------------------	-----

f. Remuneration and sitting fees to key managerial personnel

Half Year ended
30 September 2020

Salaries and other benefits*	110.0
Contributions to defined contribution plans	3.1
Director sitting fees	3.7

Note:

*Salaries and other benefits does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.



iii) Closing balances of related parties

a. Balances with Section 8 Wholly owned subsidiaries (Not Consolidated) at the period end

	As at 30 September 2020
Aurobindo Pharma Foundation	
Balance payable	10.0

b. Balances with Joint ventures at the period end

	As at 30 September 2020
Novagen Pharma (Pty) Limited, South Africa	
Balance receivable	356.7
Raidurgam Developers Limited, India	
Balance receivable	36.4
Euglia Pharma Specialities Limited, India	
Balance receivable	499.2
Balance payable	142.6
Purple Bellflower (Pty)Ltd, South Africa	
Balance receivable	0.1

c. Balances with enterprises over which key management personnel or their relatives exercise significant influence at the period end.

	As at 30 September 2020
Pravesha Industries Private Limited, India	
Balance payable	1,156.6
Sri Sai Packaging, India	
Balance payable	28.8
Axis Clinicals Limited, India	
Balance receivable	1.5
Balance payable	435.3
Axis Clinicals LLC, USA	
Balance receivable	6.8
Balance payable	227.6
Trident Chemphar Limited, India	
Balance receivable	600.6
Balance payable	27.8
Pranit Packaging Private Limited, India	
Balance receivable	0.9
Balance payable	47.2
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Balance payable	368.7
Orem Access Bio Inc, India	
Balance payable	73.0
Veritaz Healthcare Limited, India	
Balance receivable	95.6
Crest Cellulose Private Limited, India	
Balance payable	116.5
East Pharma Technologies, India	
Balance payable	19.6
Gelcaps Industries, India	
Balance payable	105.5
Giyaaan Pharma Private Limited, India	
Balance receivable	37.2
Alcedo Pharmachem Private Limited, India	
Balance payable	34.2
Ambipack Industries, India	
Balance payable	17.8

d. Balances with with key managerial personnel at the period end

	As at 30 September 2020
Balance payable	0.2

